Medicamen Organics Limited — PPTs, 23-11-2024: Investor Presentation

**H1 FY25 Investor Presentation Summary**

**Financial Highlights:** Medicamen Organics reported a total income of ₹1,686 Lakhs in H1 FY25, reflecting a robust 49% year-on-year increase. EBITDA rose 15% to ₹277 Lakhs, while net profit improved by 11% to ₹151 Lakhs. The EBITDA margin decreased from 21% to 16%, and the net profit margin dipped from 12% to 9%. Notably, the earnings per share (EPS) declined to ₹1.48.

**Strategic Initiatives and Growth Drivers:** The company aims to strengthen its market presence through expansions in product categories, including cosmetics and nutraceuticals. It plans to increase production capacity at Unit 1 by 20%, anticipating heightened demand. Additionally, Medicamen is entering new markets in Francophone Africa, targeting approximately ₹400-500 Lakhs in revenue from this region in FY25.

**Business Developments:** Medicamen has established a 51% stake in Depot Pharmacy Yego Limited in Rwanda, leveraging the region's strategic advantages for East African operations. The company has consistently supplied to various government institutions and expanded its B2B contract manufacturing partnerships.

**Market Position and Competitive Advantage:** Positioned strongly in both domestic and international markets, Medicamen maintains substantial partnerships contributing to 79% of total sales. Its robust manufacturing infrastructure and certification enhance its competitive edge.

**Investor Implications:** Given the positive financial trajectory and strategic expansions, investors may see significant opportunities for growth as the company taps into high-demand markets and broadens its product offerings. Watch closely for how these initiatives unfold in the coming quarters.